Brief: Egetis Completes U.S. Rolling NDA Submission For Emcitate
29/01/2026 06:13
Jan 29 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST: COMPLETES THE U.S. ROLLING NDA SUBMISSION FOR EMCITATE® (TIRATRICOL) FOR TREATMENT OF MCT8 DEFICIENCY ANTICIPATES REGULATORY DECISION ON NDA APPLICATION IN SEPTEMBER 2026 Source text: ID:nMFNbj5Flg Further company coverage: EGTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))